New Risk • Jun 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$48m). Earnings are forecast to decline by an average of 22% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$75.0m market cap). Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$2.36, the stock trades at a forward P/E ratio of 10x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 57% over the past three years. 공시 • Jun 02
Biote Corp. Announces Appointment of Komal Bajaj as Chief Medical Officer, Effective June 1, 2026 Biote Corp. announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joined Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving approximately one million patients. Throughout her career, Dr. Bajaj has worked at the intersection of medicine, technology, quality, and human-centered care delivery. She has led large-scale healthcare transformation initiatives involving AI governance, simulation-based workforce training, diagnostic excellence, and patient safety modernization. She also played a leadership role in the development of a prenatal molecular diagnostic assay commercialized internationally and has been instrumental in the launch of several digital health solutions focused on improving data measurement, virtual care, and health professional education. Dr. Bajaj currently serves as Professor in the Department of Obstetrics, Gynecology and Women’s Health at Albert Einstein College of Medicine and has held numerous national advisory and leadership appointments focused on healthcare quality, safety, diagnostic excellence, and innovation, including the National Academy of Medicine, the Agency for Healthcare Research and Quality (AHRQ), and The Joint Commission. She was recognized as a “Patient Safety Expert To Know” by Becker’s Hospital Review in 2024 and 2025. 공시 • Apr 23
biote Corp. to Report Q1, 2026 Results on May 06, 2026 biote Corp. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026 공시 • Apr 03
biote Corp., Annual General Meeting, May 12, 2026 biote Corp., Annual General Meeting, May 12, 2026. 공시 • Mar 12
Biote Corp. Provides Earnings Guidance for the Year 2026 Biote Corp. provided earnings guidance for the year 2026. For the year 2026, the company expects revenue of revenue of above $190 million. 공시 • Feb 26
biote Corp. to Report Q4, 2025 Results on Mar 11, 2026 biote Corp. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026 공시 • Nov 06
Biote Corp. Reiterates Earnings Guidance for the Year 2025 biote Corp. reiterated earnings guidance for the year 2025. For the year, the company expected revenue of above $190 million. 공시 • Oct 23
biote Corp. to Report Q3, 2025 Results on Nov 05, 2025 biote Corp. announced that they will report Q3, 2025 results After-Market on Nov 05, 2025 공시 • Aug 07
Biote Corp. Revises Earnings Guidance for Full Year 2025 Biote Corp. revised earnings guidance for full year 2025. For the period, the company now expects revenue Above $190 million as compared to previous guidance range of $202 million-$208 million. 공시 • Jul 24
biote Corp. to Report Q2, 2025 Results on Aug 06, 2025 biote Corp. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025 공시 • Jun 10
biote Corp. Appoints Rich Barrera to Board of Directors, Effective June 9, 2025 biote Corp. announced that its Board of Directors has elected Rich Barrera to the Board, effective June 9, 2025. Mr. Barrera is currently Founder and CEO of Roystone Capital, a New York City-based investment manager. Prior to founding Roystone in 2012, Mr. Barrera co-managed investment portfolios at Redwood Capital Management, LLC from 2009 to 2012 and at Glenview Capital Management from 2002 to 2009. Mr. Barrera served as Chair of the Finance Committee and member of the Audit Committee of Pacific Gas & Electric from 2019 to 2020. Mr. Barrera earned his MBA from Harvard Business School in 1997 and graduated from the Wharton School with a BS in Accounting and Finance in 1993. 공시 • Jun 06
biote Corp. Announces Resignation of Steven J. Heyer as a Member of the Board, Effective June 2, 2025 On June 2, 2025, Steven J. Heyer notified the Board of Directors of biote Corp. of his resignation as a member of the Board, effective June 2, 2025. Mr. Heyer's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. The Board has not yet selected a replacement to fill the vacancy. 공시 • May 08
Biote Corp. Affirms Earnings Guidance for Second Quarter and Full Year 2025 biote Corp. affirmed earnings guidance for second quarter and full year 2025. For the period, the company expects revenue in the range of $202 million - $208 million.
For the second quarter, the company expects revenue to be similar to or slightly higher than that of the second quarter of 2024. 공시 • Apr 24
biote Corp. to Report Q1, 2025 Results on May 07, 2025 biote Corp. announced that they will report Q1, 2025 results After-Market on May 07, 2025 공시 • Apr 04
biote Corp., Annual General Meeting, May 13, 2025 biote Corp., Annual General Meeting, May 13, 2025. 공시 • Mar 13
biote Corp. Provides Earnings Guidance for the Year 2025 biote Corp. provided earnings guidance for the year 2025. For the year, the company expected revenue to be $202-$208 million. 공시 • Feb 27
biote Corp. to Report Q4, 2024 Results on Mar 12, 2025 biote Corp. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025 공시 • Jul 26
biote Corp. to Report Q2, 2024 Results on Aug 08, 2024 biote Corp. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 공시 • Jun 21
biote Corp. (NasdaqGM:BTMD) announces an Equity Buyback for 8,300,000 shares, for $60 million. biote Corp. (NasdaqGM:BTMD) announces a share repurchase program. Under the program, the company will repurchase up to 8,300,000 shares for $60 million worth of its Paired Interests and/or Class A Shares from Marci M. Donovitz. The shares will be repurchased at an average price of $7.23 per share. The repurchases will be funded with its existing capital allocation strategy. The repurchase program will be valid for 3 years. 공시 • May 09
Biote Corp. Reaffirms Earnings Guidance for the Year 2024 biote Corp. reaffirmed earnings guidance for the year 2024. For the year, the company expected revenue of $200 million to $204 million. 공시 • Apr 24
biote Corp. to Report Q1, 2024 Results on May 07, 2024 biote Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024 공시 • Apr 13
biote Corp., Annual General Meeting, May 21, 2024 biote Corp., Annual General Meeting, May 21, 2024, at 10:00 Central Standard Time. Agenda: To elect three Class II directors, Steven J. Heyer, S. Mark Cone and Debra L. Morris, each to serve until our 2027 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal; to consider and ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider and transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. 공시 • Mar 15
biote Corp. (NasdaqGM:BTMD) completed the acquisition of Asteria Health. biote Corp. (NasdaqGM:BTMD) entered into a definitive agreement to acquire Asteria Health for $9 million on January 17, 2024. The consideration consists of $8.5 million in cash and $0.5 million based on certain production metrics achieved by April 1, 2024. Biote will fund the transaction with cash from its balance sheet. Asteria Helath team is joining Biote. The acquisition is subject to customary closing conditions, with closing anticipated to occur in the first quarter of 2024. Truist Securities, Inc. acted as financial advisor to biote Corp.
biote Corp. (NasdaqGM:BTMD) completed the acquisition of Asteria Health on March 14, 2024. 공시 • Mar 13
Biote Corp. Provides Revenue Guidance for 2024 biote Corp. provided revenue guidance for 2024. For the period, the company expects revenue in the range of $200-$204 million. 공시 • Feb 28
biote Corp. to Report Q4, 2023 Results on Mar 12, 2024 biote Corp. announced that they will report Q4, 2023 results After-Market on Mar 12, 2024 공시 • Jan 27
biote Corp. (NasdaqGM:BTMD) announces an Equity Buyback for $20 million worth of its shares. biote Corp. (NasdaqGM:BTMD) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its Class A common stock. 공시 • Jan 19
biote Corp. Provides Revenue Guidance for the Year 2023 biote Corp. announced that the management expects 2023 revenue to be slightly below prior guidance. The Company had previously forecast that revenue would be toward the lower end of the previously announced ranges of $190 million-$200 million. The Company now expects full year 2023 revenue of $185 million-$187 million. The Company’s expected 2023 revenue growth of approximately 12% over the prior year includes procedure revenue growth of approximately 9% and dietary supplement revenue growth of approximately 17%, as compared to the prior year. 공시 • Jan 18
Biote Corp. Provides Revenue Guidance for the Fourth Quarter of 2023, First Half and Full Year of 2024 Biote Corp. provided revenue guidance for the fourth quarter of 2023, first half and full year of 2024. The expected revenue of $45 million - $47 million for the fourth quarter of 2023 includes procedure revenue growth of approximately 7% and dietary supplement revenue decline of approximately 15% compared to same period in 2022. The decline in dietary supplement, or nutraceutical, revenue was primarily driven by one of Biote’s larger distributors recently opting to exit the nutraceutical business. Biote expects to begin direct-to-patient distribution of the products previously delivered by this distributor in the second quarter of 2024. The Company’s expected results for 2023 are preliminary and subject to adjustment as the Company finalizes its financial closing procedures and its audited consolidated financial statements for the 2023 fiscal year end. First half 2024 consolidated year-on-year revenue growth is expected to be in the low-single digits, with significant improvement expected in the second half of 2024. Total revenue growth in the first half of 2024 is expected to be impacted by the transition in the nutraceutical distribution channel and timing of seasonal promotions. Biote projects fiscal 2024 revenue of greater than $200 million. The Company’s 2024 financial guidance includes: (i) procedure revenue growth in the first half of 2024 similar to that of the second half of 2023 with improved growth in the back half of 2024; (ii) a return to nutraceutical revenue growth in the second half of 2024; (iii) expected modest contributions from new therapeutic wellness products; and (iv) a margin contribution from the anticipated impact of the acquisition of Asteria Health. 공시 • Jan 12
biote Corp. Announces Chief Financial Officer Changes biote Corp. announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote’s finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar’s transition is unrelated to the Company’s financial results or any disagreement with the Company over its accounting principles, practices or financial disclosures. Mr. Peterson brings 15 years of health and wellness industry experience as well as public company experience to Biote. Prior to joining the Company, he served as Executive Vice President, Chief Financial Officer of Virbac Corporation, a subsidiary of Virbac S.A., a global veterinary pharmaceutical and wellness company. Additionally, he spent eight years at Alcon Laboratories/Novartis Eye Care, where he held roles of progressive responsibility, including Global Head of Business Planning and Analysis as well as Finance Manager Investor Relations. 공시 • Nov 08
biote Corp. Reiterates Earnings Guidance for 2023 biote Corp. reiterated earnings guidance for 2023. For the period, the company expects revenue to be $190 million to $200 million. 공시 • Oct 25
biote Corp. to Report Q3, 2023 Results on Nov 07, 2023 biote Corp. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023 공시 • Aug 11
Biote Corp. Provides Revenue Guidance for 2023 biote Corp. provided Revenue guidance for 2023. For the year, company expects revenue to be $190 million to $200 million. 공시 • Jul 29
biote Corp. to Report Q2, 2023 Results on Aug 10, 2023 biote Corp. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 공시 • Jun 06
biote Corp. has completed a Follow-on Equity Offering in the amount of $27.913047 million. biote Corp. has completed a Follow-on Equity Offering in the amount of $27.913047 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 5,217,392
Price\Range: $5.35 공시 • May 31
Biote Corp. Appoints Mary J. Puncochar as Chief Commercial Officer biote Corp. announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote’s commercial initiatives to expand the Company’s presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biote, Ms. Puncochar served as Head of the U.S. region at Ascensia Diabetes Care, a global diabetes care company, where she achieved commercial success through the development and launch of innovative solutions and precision tools aimed at helping consumers more effectively manage their health. 공시 • May 10
biote Corp. Provides Earnings Guidance for the Year 2023 biote Corp. provided earnings guidance for the year 2023. For the year, the company expects revenue to be in the range of $190 million to $200 million. 공시 • Feb 10
biote Corp. to Report Q4, 2022 Results on Mar 28, 2023 biote Corp. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2023 공시 • Jan 07
biote Corp. has completed a Follow-on Equity Offering in the amount of $22.173915 million. biote Corp. has completed a Follow-on Equity Offering in the amount of $22.173915 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 7,391,305
Price\Range: $3
Discount Per Security: $0.18 공시 • Nov 09
biote Corp. Revises Earnings Guidance for the Full Year 2022 biote Corp. revised earnings guidance for the full year 2022. Based on the strong year-to-date performance and expectations for the fourth quarter, the company expects to achieve the upper end of the Company's previously issued 2022 financial guidance ranges of $160 million to $166 million in revenue. 공시 • Nov 08
biote Corp. Appoints Debra L. Morris to the Board and as a Member of Audit Committee On November 3, 2022, the Board of Directors of biote Corp. increased the size of the Board from six to seven directors and, following the recommendation of the Nominating and Corporate Governance Committee, appointed Debra L. Morris to serve as a member of the Board and as a member of the Board’s Audit Committee, effective immediately. Ms. Morris is a Class II director whose term will expire at the Company’s 2023 Annual Meeting of Stockholders. The Board has determined that Ms. Morris is “independent” pursuant to the rules of The Nasdaq Stock Market LLC and other governing laws and applicable regulations. Ms. Morris, age 63, served as the executive vice president and chief financial officer of Apria Inc. from March 2013 through October 2022. Prior to that, Ms. Morris served as Chief Financial Officer-Americas for Sitel Worldwide Corporation from February 2010 to February 2013. Prior to that she served as a partner of Tatum LLC from 2004 to 2010 and as a director from 2008 to 2010 and provided interim and permanent chief financial officer services for companies contracted with Tatum LLC including LifeMasters Supported SelfCare and RelaDyne. Effective May 15, 2020, Ms. Morris serves as a director for Alternative Logistics Technologies, Holdco, LLC (a.k.a EverDriven) and serves as the chair of the audit committee. Effective December 31, 2020, Ms. Morris serves as a director for Rexford Industrial (REXR) and serves on the audit, compensation and nomination and governance committees. Ms. Morris holds a B.S. in Business Administration from Colby Sawyer College in New London, New Hampshire. 공시 • Nov 01
biote Corp. to Report Q3, 2022 Results on Nov 08, 2022 biote Corp. announced that they will report Q3, 2022 results After-Market on Nov 08, 2022 공시 • Aug 30
biote Corp. Class A Common Stock Deleted from OTC Equity biote Corp. Class A Common Stock has been deleted from OTC Equity effective from August 29, 2022, due to Market Center Change Listed on NASDAQ. 공시 • Aug 25
biote Corp. Announces CFO Changes biote Corp. announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee Biote's financial operations with a focus on driving revenue growth and profitability, and will report to the Company's Chief Executive Officer, Terry Weber. Mr. Kamdar brings to Biote a deep knowledge of financial leadership experience across industries including healthcare information technology, consumer packaged goods, retail services and software industries, with a proven track record of building high-performance teams and driving business transformation and growth. Most recently, Mr. Kamdar served as Chief Financial Officer at Slync.io, where he led the company’s financial operations. Previously, Mr. Kamdar was Chief Financial Officer at TaxAct. Mr. Kamdar has also held roles at CROSSMARK, an internet-based health information exchange services provider. Mr. Kamdar also spent six years at PepsiCo in a number of financial roles, including corporate planning and asset strategy. Mr. Kamdar holds a Bachelor of Science in electrical engineering from Baylor University, and a Master of Business Administration from the University of Texas, McCombs School of Business. On August 24, 2022, the Company announced the appointment of Samar Kamdar as Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately. Mr. Kamdar will succeed Robbin Gibbins who is currently expected to stay with the Company through November 15, 2022 to assist with the transition and work on special projects. Robbin Gibbins, the Company's current Chief Financial Officer, will transition out of his role, effective immediately. However, Mr. Gibbins is currently expected to remain employed by the Company through November 15, 2022. Mr. Gibbins' transition is by mutual agreement with the Company and is unrelated to the Company's quarterly financial results or any disagreement with the Company over its accounting principles, practices or financial disclosures. 공시 • Aug 10
Biote Corp. Reiterates Earnings Guidance for the Year 2022 biote Corp. reiterated earnings guidance for the year 2022. For the year, company reiterates its previous revenue guidance of $160 million - $166 million. 공시 • Jul 20
Nasdaq to Delist Class A Common Stock and Warrant of biote Corp As previously disclosed, on May 26, 2022, biote Corp. (the “ Company”) received written notice (the “ Notice”) from the Staff of the Listing Qualifications Department (the “ Staff”) of the Nasdaq Stock Market LLC (“ Nasdaq”) stating that the Staff has determined that the Company has not complied with the requirements of IM-5101-2 because (i) the Company has not demonstrated that its Class A common stock complies with (a) the minimum 400 Round Lot Holder requirement in Listing Rule 5405(a)(3) (the “ Round Lot Holder Requirement”) and (b) the minimum $20 million in Market Value of Unrestricted Publicly Held Shares requirement in Listing Rule 5405(b)(3)(B) (the “ Market Value of Unrestricted Publicly Held Shares Requirement” and, together with the Round Lot Holder Requirement, the “ Exchange Requirements”) and (ii) the Company’s warrants do not qualify for initial listing since the security underlying the warrant, the Company’s Class A common stock, does not qualify. The Company requested, and received, a hearing with the Hearings Panel (the “ Panel”) on June 30, 2022 to appeal Nasdaq’s determination, which request stayed the suspension of the Company’s Class A common stock and warrants and the filing by Nasdaq of a Form 25-NSE pending the Panel’s decision. On July 18, 2022, the Company received the determination letter (the “ Determination Letter”) from the Panel to delist the Company’s Class A common stock and warrants from Nasdaq (the “ Panel’s Determination”). The Determination Letter indicated Nasdaq will suspend trading in Company’s Class A common stock and warrants effective at the open of business on July 20, 2022, and indicated that it intends to file a Form 25 NSE Notification of Delisting with the Securities and Exchange Commission (the “ SEC”) once all applicable appeal and review periods have expired in order to effect the formal delisting of the Company’s securities from Nasdaq. The Company believes it is already in compliance with the Round Lot Holder Requirement and additionally expects to comply with the Market Value of Unrestricted Publicly Held Shares Requirement on Tuesday, July 19, 2022. Given the foregoing, the Company intends to timely request an appeal by the Nasdaq Listing and Hearing Review Council of the Panel’s Determination in light of the fact that the Company would comply with Nasdaq’s listing requirements prior to the time the suspension of trading in the Company’s Class A common stock on Nasdaq. Upon suspension from Nasdaq, the Company expects its securities to begin trading on the OTC Markets’ “OTC Pink Market” tier. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improved over the past week After last week's 15% share price gain to US$4.98, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 49% over the past year. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment deteriorated over the past week After last week's 23% share price decline to US$3.45, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in the US. Total loss to shareholders of 65% over the past year. 공시 • Jun 17
biote Corp. Appoints Ross W. McQuivey, M.D. as Chief Medical Officer, Effective June 10, 2022 biote Corp. appointed Ross W. McQuivey, M.D., as its Chief Medical Officer, effective June 10, 2022. Dr. McQuivey will be responsible for leading continuing clinical research efforts and publications. The Company also expects that he be instrumental in expanding the Biote Method to mainstream medicine. Dr. McQuivey brings to Biote more than 20 years of medical and scientific leadership in the healthcare industry, with management experience in research and development, medical affairs, as well as regulatory and quality control. He has published over a dozen peer-reviewed journal articles, abstracts and poster presentations, and has lectured extensively in the United States and internationally. Prior to joining Biote, Dr. McQuivey served as Chief Medical Officer of Laborie Medical Technologies, a global medical technology company focused on urology, urogynecology, gastroenterology, obstetrics, gynecology and neonatal health. He previously held multiple roles of increasing responsibility at Clinical Innovations, LLC, a provider of products for the labor and delivery and neonatal intensive care unit specialties, from 2003 to 2020, with his last position as Chief Medical Officer before the company was acquired. He has held various board positions, including the Journal of Clinical Obstetrics, Gynecology & Infertility, Patient Safety Movement Foundation and the National Patient Safety Council. Additionally, Dr. McQuivey is a member of the American College of Obstetrics and Gynecology (“ACOG”), the American Medical Association and the Society of Simulation in Healthcare. Previously, he was also a member of the Utah Medical Association and the Utah Section ACOG. Dr. McQuivey earned his Doctor of Medicine from the University of Utah School of Medicine and holds a Bachelor of Arts in psychology from Stanford University. 공시 • Jun 05
Biote Corp. Announces Board Changes biote Corp. announced that Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, (i) each executive officer of HYAC ceased serving in such capacities, (ii) each member of the board of directors of HYAC ceased serving in such capacity, (iii) Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company, and (iv) Marc Beer was appointed Executive Chairman of the Board. 
